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A bs tr ac t
Background
Hodgkin’s lymphoma and anaplastic large-cell lymphoma are the two most com-
mon tumors expressing CD30. Previous attempts to target the CD30 antigen with 
monoclonal-based therapies have shown minimal activity. To enhance the antitumor 
activity of CD30-directed therapy, the antitubulin agent monomethyl auristatin E 
(MMAE) was attached to a CD30-specific monoclonal antibody by an enzyme-cleav-
able linker, producing the antibody–drug conjugate brentuximab vedotin (SGN-35).
Methods
In this phase 1, open-label, multicenter dose-escalation study, we administered 
brentuximab vedotin (at a dose of 0.1 to 3.6 mg per kilogram of body weight) every 
3 weeks to 45 patients with relapsed or refractory CD30-positive hematologic can-
cers, primarily Hodgkin’s lymphoma and anaplastic large-cell lymphoma. Patients 
had received a median of three previous chemotherapy regimens (range, one to 
seven), and 73% had undergone autologous stem-cell transplantation.
Results
The maximum tolerated dose was 1.8 mg per kilogram, administered every 3 weeks. 
Objective responses, including 11 complete remissions, were observed in 17 patients. 
Of 12 patients who received the 1.8-mg-per-kilogram dose, 6 (50%) had an objective 
response. The median duration of response was at least 9.7 months. Tumor regres-
sion was observed in 36 of 42 patients who could be evaluated (86%). The most com-
mon adverse events were fatigue, pyrexia, diarrhea, nausea, neutropenia, and periph-
eral neuropathy.
Conclusions
Brentuximab vedotin induced durable objective responses and resulted in tumor 
regression for most patients with relapsed or refractory CD30-positive lymphomas 
in this phase 1 study. Treatment was associated primarily with grade 1 or 2 (mild-
to-moderate) toxic effects. (Funded by Seattle Genetics; ClinicalTrials.gov number, 
NCT00430846.)
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A pproximately 15 to 30% of patients with Hodgkin’s lymphoma do not have a long-term remission with conventional 
therapy,1 resulting in an estimated 1300 deaths 
annually in the United States alone.2 Autologous 
hematopoietic stem-cell transplantation (ASCT) 
represents a potentially curative treatment for some 
patients with recurrent or progressive Hodgkin’s 
lymphoma after failure of initial combination 
chemotherapy. Unfortunately, ASCT is only effec-
tive in approximately 50% of such patients.3,4 
Among those who have a relapse after ASCT, 
overall survival is 55% at 2 years and 32% at 
5 years.5 Because the incidence of Hodgkin’s lym-
phoma peaks during young adulthood, these pre-
mature deaths have a substantial social impact.6
In Hodgkin’s lymphoma, malignant Hodgkin’s 
Reed–Sternberg (HRS) cells typically represent a 
small fraction (0.1 to 10%) of the nodal infiltrate.7 
HRS cells reside among reactive inflammatory 
cells, consisting of a dense infiltrate of T cells, 
histiocytes, eosinophils, and plasma cells. HRS 
cells appear to attract these cells to the microen-
vironment by secreting type 2 helper T chemo-
kines and cytokines, such as thymus and activa-
tion-regulated chemokine (TARC, or CCL17). In 
turn, the immune cells appear to support the HRS 
cells by secreting survival factors.8,9 Conceivably, 
the ablation of HRS cells could prompt nodal re-
gression and potentially result in prolonged clini-
cal remission.
CD30 is expressed on the surface of HRS cells 
and cells in anaplastic large-cell lymphomas 
(ALCLs), embryonal carcinomas, and select sub-
types of B-cell derived, non-Hodgkin’s lympho-
mas and mature T-cell lymphomas.10-12 Because 
normal expression of CD30 is highly restricted to 
a relatively small population of activated B cells 
and T cells and a small portion of eosinophils,10-12 
the deletion of CD30-expressing cells could rep-
resent a novel and selective treatment strategy. 
Although preclinical data suggested that uncon-
jugated anti–CD30 antibodies might have thera-
peutic value,13 minimal clinical activity has been 
reported. Objective responses were observed in 
6% of patients with Hodgkin’s lymphoma who 
were treated with MDX-06014 and in none of 
those treated with SGN-30 (monoclonal antibody 
cAC10).15
To enhance antitumor activity, the antitubulin 
agent monomethyl auristatin E (MMAE) was at-
tached to the CD30-specific monoclonal antibody 
cAC10 by an enzyme-cleavable dipeptide linker,16 
producing the antibody–drug conjugate brentux-
imab vedotin (SGN-35, Seattle Genetics).17 After 
binding CD30, the antibody–drug conjugate is 
rapidly internalized and is transported to lyso-
somes, where the peptide linker is selectively 
cleaved. MMAE is then released into the cell, binds 
tubulin, and prompts arrest of the cell cycle be-
tween the gap 2 phase and mitosis (G2/M) and cell 
apoptosis (Fig. 1 in the Supplementary Appendix, 
available with the full text of this article at NEJM 
.org). In vitro, the drug was found to be potent and 
selective against CD30-positive tumor-cell lines, 
and activity was observed in models of Hodgkin’s 
lymphoma and ALCL in mice with severe com-
bined immunodeficiency.18-20
To assess the safety and clinical activity of 
brentuximab vedotin, we treated patients with re-
lapsed or refractory CD30-positive hematologic 
cancers in a phase 1, open-label, dose-escalation 
trial. Furthermore, because serum levels of TARC 
have been shown to correlate with disease activ-
ity in patients with Hodgkin’s lymphoma,21,22 we 
evaluated serum levels of TARC and various cyto-




From November 2006 through July 2009, we col-
lected data at four study centers in the United 
States. Patients had relapsed or refractory, histo-
logically confirmed CD30-positive hematologic 
cancers. Patients with Hodgkin’s lymphoma had 
received systemic chemotherapy either as induc-
tion therapy for advanced-stage disease or salvage 
therapy after initial radiotherapy for early-stage 
disease and had previously undergone ASCT un-
less they were ineligible or declined treatment. 
Patients with other CD30-positive cancers, such 
as systemic ALCL, had already had a first remis-
sion or had disease refractory to front-line chemo-
therapy.
To be eligible for study enrollment, patients 
needed to be at least 18 years of age, have a mea-
surable tumor of at least 10 mm in diameter, and 
have an Eastern Cooperative Oncology Group per-
formance status of 2 or less (on a scale of 0 to 
5, with higher scores indicating more severe dis-
ability).23 Patients were excluded if they had un-
dergone allogeneic stem-cell transplantation.
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Study Design
The primary objectives of the study were to define 
the safety profile of brentuximab vedotin and to 
determine the maximum tolerated dose (the 
highest dose that would not produce unaccept-
able toxic effects). Secondary objectives were to 
determine pharmacokinetic measures for the anti-
body–drug conjugate and MMAE, evaluate im-
munogenicity, and assess antitumor response. 
Exploratory analysis of cytokines and chemokines 
was limited to patients in the expansion phase of 
the study.
Brentuximab vedotin was administered intra-
venously at doses of 0.1 to 3.6 mg per kilogram 
of body weight every 3 weeks (one cycle); pre-
medication was not required. The study used a 
traditional dose-escalation design, followed by 
a cohort expansion phase. Dose-limiting toxic 
effects, which were assessed during the 21-day 
observation period of cycle 1, included related non-
hematologic events of grade 3 or higher, clinically 
significant grade 3 or 4 neutropenia or febrile 
neutropenia, and grade 4 thrombocytopenia. (Ad-
ditional details about dose-limiting toxic effects 
are provided in Table 1 in the Supplementary Ap-
pendix.) If 1 of the first 3 patients had a dose-
limiting toxic effect, the cohort was expanded to 
6 patients. If at least 2 of 6 patients within a co-
hort had a dose-limiting toxic effect, the maxi-
mum tolerated dose was considered to have been 
exceeded. After the maximum tolerated dose was 
exceeded, additional patients were to be enrolled 
at the preceding dose for a total of 12 patients; 
an additional cohort at a lower dose level also 
could be expanded.
Response was assessed every 6 weeks. Patients 
with complete remission, partial remission, or 
stable disease with protocol-defined clinical ben-
efit (improved performance status, decreased anal-
gesic consumption, or decreased disease volume) 
could continue therapy. Study treatment was dis-
continued on confirmation of disease progression. 
After treatment discontinuation, patients were 
monitored for a minimum of 30 days after the 
last dose of brentuximab vedotin or until they 
received another treatment for lymphoma.
Study Assessments
Safety monitoring included the assessment of ad-
verse events, dose-limiting toxic effects, and clini-
cal laboratory values. Adverse events were sum-
marized according to terms used in the Medical 
Dictionary for Regulatory Activities, version 11.1, and 
graded according to the National Cancer Insti-
tute’s Common Terminology Criteria for Adverse 
Events, version 3.24
Serum concentrations of brentuximab vedotin 
were assessed with the use of a validated enzyme-
linked immunosorbent assay (ELISA). Derived 
pharmacokinetic measures were estimated by 
means of noncompartmental methods (Win-
Nonlin, Pharsight). Immunogenicity to brentux-
imab vedotin was assessed before each dose by 
means of a validated ELISA.
The best clinical response was determined by 
the academic investigators. The definition of a best 
clinical response was based on the 2007 Revised 
Response Criteria for Malignant Lymphoma.25 
A complete response was defined as the disap-
pearance of all evidence of disease, a partial re-
sponse as a decrease of at least 50% in the sum 
of the product of diameters of measurable target 
lesions and no new lesions, stable disease as the 
lack of a complete or partial response and no oc-
currence of progressive disease, and progressive 
disease as any new lesion or an increase of at least 
50% in the sum of the product of diameters of 
previously involved sites.25 An independent review 
facility (RadPharm) retrospectively evaluated the 
radiographic scans.
Cytokines and chemokines, including tumor 
necrosis factor α (TNF-α), interleukins (1β, 2, 6, 
and 8), granulocyte–macrophage colony-stimulat-
ing factor, interferon-gamma, and TARC were 
evaluated for patients in the expansion phase of 
the study (six patients each in the 1.8-mg cohort 
and the 2.7-mg cohort). Serum samples were 
drawn at baseline, before and 4 hours after each 
dose of the study drug, and at the end of treat-
ment. TARC was measured by means of ELISA 
(R&D Systems), and cytokines were measured by 
means of electrochemiluminescence assays (Meso 
Scale Diagnostics). These assays were performed 
by an independent laboratory after study com-
pletion.
Study Oversight
The study was sponsored by Seattle Genetics. The 
academic investigators and the sponsor were jointly 
responsible for the study design. The academic 
investigators collected the data, and the sponsor 
verified the accuracy of the data. One of the aca-
demic authors and a representative of the spon-
sor wrote the first draft of the manuscript, which 
was finalized and approved by all authors. Rep-
resentatives of the sponsor conducted and verified 
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the statistical analyses and provided assistance 
in the preparation of the manuscript, including 
the services of a paid consultant who assisted in 
the editorial and submission process. All authors 
had full access to the data, contributed to the in-
terpretation, and vouch for the completeness and 
accuracy of the results and the adherence of the 
reported results to the final protocol. The proto-
col was approved by the institutional review board 
at each study site, and all patients provided writ-
ten informed consent before study-specific pro-
cedures began. The protocol and statistical analy-
sis plan are available at NEJM.org.
R esult s
Patients
Of the 45 patients who were treated, 42 had Hodg-
kin’s lymphoma, 2 had systemic ALCL, and 1 had 
CD30-positive angioimmunoblastic T-cell lympho-
ma (Table 1). The median age of the patients was 
36 years (range, 20 to 87). Patients had undergone 
a median of 3 previous chemotherapy regimens 
(range, 1 to 7), and 33 patients (73%) had under-
gone previous autologous stem-cell transplant-
ation.
Safety Profile and Maximum Tolerated Dose
A dose-limiting toxic effect (grade 4 thrombocy-
topenia) occurred in 1 of 6 patients who received 
a dose of 1.8 mg per kilogram; unrelated grade 3 
acute renal failure occurred in 1 of 6 patients who 
received a dose of 2.7 mg per kilogram. In the sin-
gle patient who received a dose of 3.6 mg per kilo-
gram, febrile neutropenia and presumed sepsis 
developed, which both contributed to death 14 days 
after the first dose. Subsequently, the 1.8-mg and 
2.7-mg cohorts were both expanded to include 12 
patients each. At the 2.7-mg dose, 2 additional pa-
tients had three dose-limiting toxic effects (grade 
3 hyperglycemia in the first patient and grade 3 
unrelated prostatitis and febrile neutropenia in 
the second patient) for a total of 3 of 12 patients 
with dose-limiting toxic effects at this dose level. 
On the basis of these observations, a dose of 
2.7 mg per kilogram was associated with unac-
ceptable toxic effects, and 1.8 mg per kilogram 
was considered the highest dose that did not 
cause unacceptable adverse effects.
The most common adverse events, typically 
grade 1 or 2 in severity, were fatigue (16 patients, 
36%), pyrexia (15 patients, 33%), and diarrhea, 
nausea, neutropenia, and peripheral neuropathy 
(10 patients, 22% each) (Table 2). A total of 27 
serious adverse events occurred in 14 patients 
(31%) during the study (Table 2 in the Supple-
mentary Appendix); of these events, 9 (33%) were 
Table 1. Demographic and Clinical Characteristics of the 45 Patients.
Characteristic Value
Age
Median — yr 36
Range — yr 20–87
≤65 yr — no. (%) 41 (91)
Sex — no. (%)
Male 28 (62)
Female 17 (38)




Diagnosis — no. (%)
Hodgkin’s lymphoma 42 (93)
Anaplastic large-cell lymphoma (systemic) 2 (4)†
Angioimmunoblastic T-cell lymphoma 1 (2)
Time since initial diagnosis — mo
Median 39
Range 8–253





Tumor burden (sum of product of diameters) — cm2
Median 22.24
Range 2.83–179.78
Patients with fever, night sweats, or weight loss — no. (%) 16 (36)
Previous therapy
Systemic chemotherapy — no. (%) 45 (100)
Median no. of therapies 3
Range 1–7
Autologous stem-cell transplantation — no. (%) 33 (73)
Radiotherapy — no. (%) 27 (60)
Cancer-related surgery — no. (%) 14 (31)
* Eastern Cooperative Oncology Group (ECOG) performance scores range from 
0 (normal activity) to 5 (death), with higher scores indicating more severe dis-
ability.
† Both patients with anaplastic large-cell lymphoma tested positive for anaplastic 
lymphoma kinase (ALK) protein.
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considered by the investigators to be related to 
the study drug. The most commonly observed 
laboratory abnormalities of grade 3 or higher are 
provided in Table 3 in the Supplementary Ap-
pendix.
Dose delays because of adverse events occurred 
in 16 patients (36%). A total of 12 patients (27%) 
had adverse events other than progression that led 
to treatment withdrawal, including 2 patients each 
with fatigue and thrombocytopenia. One patient 
discontinued treatment after having an anaphy-
lactic reaction during administration of the sec-
ond 1.8-mg dose. The administration of a dose 
was interrupted in another patient in the same 
cohort because of an infusion-related reaction; 
after receiving treatment for the reaction, the 
patient recovered for approximately 2 hours and 
then the infusion was restarted without further 
incident.
Peripheral neuropathy and associated adverse 
events related to neuropathy were reported in 16 
patients (36%), 13 of whom were treated at the 
1.8-mg or 2.7-mg dose. Patients with peripheral 
neuropathy typically presented with grade 1 or 2 
sensory findings, such as numbness or tingling 
in the hands or feet, and the median time to on-
set was 9 weeks (range, 3 to 24). Resolution of 
peripheral neuropathy was noted in 10 of 16 pa-
tients (63%) at the last safety assessment; 3 pa-
tients had ongoing asymptomatic grade 1 find-
ings, and 3 patients had persistent grade 2 
symptoms that were considered to be clinically 
significant. Three patients discontinued treatment 
because of peripheral neuropathy (grade 2 periph-
eral neuropathy, grade 2 peripheral sensory neu-
ropathy, and grade 3 peripheral sensorimotor 
neuropathy). Of note, the only grade 3 event, which 
was observed in a patient in the 2.7-mg cohort, 
returned to grade 1 after approximately 4 months.
All patients tested negative for antitherapeutic 
antibody at baseline. Of the 40 patients who were 
tested, 2 (5%) were found to have a low titer of 
antitherapeutic antibody during the study; both 
of these patients had a best clinical response of 
stable disease. One patient in the 0.1-mg cohort 
tested positive for antitherapeutic antibody from 
cycle 6 through cycle 16. The other patient, who 
was in the 1.2-mg cohort, tested positive after 
four cycles of the study drug. Because of the low 
incidence of detection of antitherapeutic antibody, 
no conclusions can be drawn regarding the po-
tential effect of the presence of antitherapeutic 
antibody on safety or activity of the study drug.
Pharmacokinetics and Pharmacodynamics
Increases in exposure to the antibody–drug con-
jugate and free MMAE were approximately pro-
portional to dose. The median time to maximum 
concentration occurred immediately after infusion 
for the antibody–drug conjugate and approximately 
2 to 3 days after infusion for MMAE. Steady-state 
pharmacokinetics for both the antibody–drug 
conjugate and MMAE occurred by approximately 
21 days, consistent with the half-life estimates of 
4 to 6 days and 3 to 4 days, respectively. Concen-
tration–time curves and pharmacokinetic mea-
sures are provided in the Supplementary Appendix 
(Fig. 2 and Table 4, respectively).




















Complete remission 0 0 0 0 0 1† 4 6† 0
Partial remission 0 0 0 2 0 1 2 1 0
Stable disease 2 0 2 1 2 2 5 5 0
Progressive disease 1 4‡ 1 0 1 0 1 0 0
Could not be evaluated 0 0 0 0 0 0 0 0 1§
* The best clinical response was determined by investigators on the basis of the 2007 Revised Response Criteria for 
Malignant Lymphoma.25
† Both patients with systemic anaplastic large-cell lymphoma (one each in the 1.2-mg cohort and the 2.7-mg cohort) had 
a complete remission.
‡ One patient with angioimmunoblastic T-cell lymphoma (in the 0.2-mg cohort) had a best clinical response of progres-
sive disease.
§ Postbaseline disease assessment was not available for the patient who received a dose of 3.6 mg per kilogram.
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Decreases in serum TARC levels were observed 
in all 12 patients for whom data were collected 
(Fig. 3 in the Supplementary Appendix). Post-
baseline decreases in levels of interleukin-6 and 
TNF-α also were noted in 10 of 12 patients each 
(data not shown).
Antitumor Response
Objective responses were noted in 17 patients, 
including 11 complete remissions (Table 3). Data 
on previous therapies, baseline disease character-
istics, and treatment response for all patients who 
had an objective response are provided in Table 4. 
For patients who received the maximum tolerat-
ed dose (1.8 mg per kilogram), the objective re-
sponse rate was 50% (6 of 12 patients). Complete 
remission occurred in patients with bulky disease 
as well as those with widespread nodal disease 
(Fig. 4 in the Supplementary Appendix). Of the 
17 patients with an objective response, 15 (88%) 
Table 4. Previous Therapy, Disease Characteristics, and Treatment Response in 11 Patients with Complete Remission and 6 Patients 
with Partial Remission.*
Response and Diagnosis Previous Therapy†
Duration of Response 




Anaplastic large-cell lymphoma CHOP, radiotherapy, ICE, cyclophosphamide–etoposide, ASCT 15 (partial response)
Hodgkin’s lymphoma ABVD, radiotherapy, ICE, ASCT 8 (complete response)
Hodgkin’s lymphoma ABVD, ICE, ASCT NA (progressive disease)
Hodgkin’s lymphoma ABVD, radiotherapy, ICE, ASCT 10 (complete response)
Hodgkin’s lymphoma ABVD, radiotherapy, ABVD, radiotherapy, radiotherapy, R-ESHAP, GND,  
ifosfamide–etoposide, GND
24 (complete response)
Hodgkin’s lymphoma ABVD, ASCT, interleukin-2, carboplatin–etoposide–prednisone 1 (partial response)
Anaplastic large-cell lymphoma CHOP 3.5 (complete response)
Hodgkin’s lymphoma ABVD, doxorubicin–bleomycin–dacarbazine, ICE, ASCT 12 (partial response)
Hodgkin’s lymphoma ABVD, radiotherapy, ICE, ASCT, MGCD-0103 3 (stable disease)
Hodgkin’s lymphoma ABVD, ICE, ASCT, gemcitabine–vinorelbine, MGCD-0103 12 (complete response)




Hodgkin’s lymphoma ABVD 17 (partial response)
Hodgkin’s lymphoma BEAM, ABVD, IVE, ASCT, radiotherapy, ESHAP, radiotherapy, gemcitabine 28 (complete response)
Hodgkin’s lymphoma ABVD, ESHAP, gemcitabine–cisplatin–dexamethasone, cyclophosphamide–
etoposide, ASCT
7 (complete response)
Hodgkin’s lymphoma ABVD, radiotherapy, ICE, cisplatin–gemcitabine, ASCT 2 (complete response)
Hodgkin’s lymphoma ABVD, radiotherapy, ESHAP, radiotherapy, ASCT, radiotherapy 17 (complete response)
Hodgkin’s lymphoma Stanford V, radiotherapy, ESHAP, IGEV, MGCD-0103 NA (progressive disease)
* ABVD denotes doxorubicin, bleomycin, vinblastine, and dacarbazine, ASCT autologous stem-cell transplantation, BEAM carmustine, etopo-
side, cytarabine, and melphalan, CHOP cyclophosphamide, doxorubicin, vincristine, and prednisone, ESHAP etoposide, methylpredniso-
lone, cytarabine, and cisplatin, GDP gemcitabine, dexamethasone, and cisplatin, GND gemcitabine, vinorelbine, and doxorubicin, hyper-
CVAD cyclophosphamide, vincristine, doxorubicin, dexamethasone, cytarabine, and methotrexate followed by methotrexate, leucovorin, and 
cytarabine, ICE ifosfamide, carboplatin, and etoposide, IGEV ifosfamide, gemcitabine, vinorelbine, and prednisone, IVE ifosfamide, etopo-
side, and epirubicin, MGCD-0103 oral histone deacetylase inhibitor, NA not applicable, R-ESHAP rituximab and ESHAP, and Stanford V 
bleomycin, doxorubicin, etoposide, mechlorethamine, prednisone, vinblastine, and vincristine.
† Previous therapies are listed in sequential order of administration.
‡ Tumor burden was measured as the sum of the products of bidimensional measurements of target lesions.
§ Each dose could be delayed up to 2 weeks to allow for resolution of toxic effects of grade 2 or higher.
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Site of Measurable 
Tumors at Baseline
Disease Burden  
at Baseline‡












cm2 mg/kg no. mo
Nodal 9.07 1.2 14 11.3 1.1 17.3
Lung, pelvis, other 
(not specified)
10.58 1.8 5 4.8 1.4 16.0+
Nodal 6.15 1.8 11 9.7 2.6 9.7
Nodal 40.48 1.8 12 9.7 2.7 19.5+
Nodal 2.83 1.8 6 4.6 1.2 13.8+
Nodal 9.96 2.7 7 6.3 6.3 13.3+
Nodal 9.00 2.7 3 2.5 1.2 5.0
Nodal 9.22 2.7 6 4.4 1.7 1.4+
Nodal 69.44 2.7 8 6.2 1.2 3.4
Nodal 3.52 2.7 3 3.0 1.7 13.3+
Nodal 52.98 2.7 4 4.0 1.4 9.0
Pelvis 8.92 0.6 2 2.0 1.2 0.6
Nodal 112.06 0.6 8 6.2 1.4 9.6
Nodal 7.40 1.2 5 4.0 3.3 1.1+
Lung 24.78 1.8 8 6.3 1.2 5.1
Nodal 22.24 1.8 2 1.8 1.7 14.6+
Nodal 27.18 2.7 10 9.5 2.7 11.5+
had an initial response within four treatment 
cycles (2.8 months). In addition, 19 of 44 patients 
who could be evaluated (43%) had stable disease.
Tumor regression, as observed on computed 
tomography (CT), was reported for 36 of 42 pa-
tients who could be evaluated (86%) (Fig. 5 in the 
Supplementary Appendix). Of 16 patients with 
disease-related symptoms at baseline, 13 (81%) 
had resolution of symptoms during treatment, re-
gardless of response status.
An independent, retrospective assessment of CT 
and positron-emission tomographic scans for the 
45 patients showed response rates similar to those 
reported by investigators, with responses report-
ed for 18 patients (40%), as compared with 17 
patients (38%) reported by investigators. For the 
12 patients who received the 1.8-mg dose, inde-
pendent reviewers reported a response in 8 pa-
tients (67%), as compared with 6 patients (50%) 
reported by investigators. Among 41 patients for 
whom evaluations by both investigators and in-
dependent reviewers were available, there was a 
significant correlation between the findings of 
the independent reviewers and those of the in-
vestigators with respect to the maximum reduc-
tion in target lesions (Pearson correlation, 0.719; 
95% confidence interval, 0.528 to 0.841).
The Kaplan–Meier estimate for the duration 
of objective response was 17.3 months for the 17 
patients with an objective response (range, 0.6 to 
>19.5) (Fig. 6 in the Supplementary Appendix). The 
median duration of objective response was at least 
9.7 months on the basis of a conservative analy-
sis that assumed progression on the date of data 
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censoring (i.e., for patients who discontinued the 
study for reasons other than documented progres-
sion or death). The median progression-free sur-
vival was 5.9 months, with a trend toward longer 
progression-free survival in patients receiving dos-
es of at least 1.2 mg per kilogram (Fig. 7 in the 
Supplementary Appendix).
Discussion
Tumor regression was observed in the majority 
of patients who were treated with brentuximab 
vedotin, which was associated mainly with grade 
1 or 2 fatigue, pyrexia, diarrhea, nausea, neutro-
penia (with one grade 3 event), and peripheral 
neuropathy at the maximum tolerated dose. Ob-
jective responses, including 11 complete remis-
sions, were observed in 17 patients; of 12 patients 
receiving the maximum tolerated dose, 6 (50%) 
had an objective response. Lending validity to 
these results, an independent, retrospective radio-
graphic review corroborated the rate of response 
and reduction in target lesions. The objective re-
sponse rate in patients receiving brentuximab ve-
dotin who had undergone previous intensive ther-
apies for Hodgkin’s lymphoma and systemic ALCL 
is particularly striking in comparison with the 
minimal activity elicited by the same unconjugat-
ed anti-CD30 monoclonal antibody (Table 5), sug-
gesting the essential contribution of the selective-
ly delivered cytotoxic agent.
Remissions were durable in this population of 
patients who had relapsed or refractory disease, 
with a median duration of at least 9.7 months. 
Responses that were associated with modest dura-
bility have been reported in monotherapy case 
series evaluating gemcitabine, vinorelbine, or vin-
blastine.26-31 Combination regimens (e.g., gem-
citabine, vinorelbine, and pegylated liposomal 
doxorubicin) have shown somewhat higher re-
sponse rates but have been associated with sub-
stantial toxic effects.32 However, complete remis-
sions are rare in patients with drug-refractory 
Hodgkin’s lymphoma or systemic ALCL, especially 
in those treated with single agents.
It has been reported that HRS cells secrete cy-
tokines and chemokines, leading to an inflam-
matory infiltrate that enhances survival of can-
cer cells.9 Treatment with brentuximab vedotin 
led to the resolution of large tumor masses and 
decreases in levels of chemokines and inflamma-
tory cytokines in patients with Hodgkin’s lym-
phoma, providing clinical data supporting the 
hypothesis that selective ablation of CD30-posi-
tive HRS cells leads to subsequent resolution of 
the inflammatory infiltrate.
Most adverse events were managed through 
standard supportive care, and the most common 
events were typically of grade 1 or 2. The most 
clinically meaningful adverse events were cumu-
lative, dose-related grade 1 or 2 peripheral neu-
ropathy and associated adverse events related to 
neuropathy. Since the cytotoxic component of 
brentuximab vedotin is a potent antitubulin agent, 
the peripheral neuropathy observed in this study 
is consistent with a class effect of microtubule 
inhibitors.33,34 Resolution of symptoms was ob-
served in the majority of patients during follow-
up, although clinically significant grade 2 symp-
toms persisted in three of six patients at the last 
safety assessment.
In conclusion, the novel antibody–drug conju-
Table 5. Clinical Activity of Brentuximab Vedotin, as Compared 





No. of patients 79 28
Objective response — no. (%)
Any 7 (9) 15 (54)
Complete remission 2 (3) 11 (39)
Partial remission 5 (6) 4 (14)
Hodgkin’s lymphoma
No. of patients 38 26
Objective response — no. (%)
Any 0 13 (50)
Complete remission 9 (35)
Partial remission 4 (15)
Anaplastic large-cell lymphoma
No. of patients 41 2
Objective response — no. (%)
Any 7 (17) 2 (100)
Complete remission 2 (5) 2 (100)
Partial remission 5 (12)
* The results for SGN-30, an unconjugated anti-CD30 monoclonal antibody 
(cAC10) administered at a dose of 6 or 12 mg per kilogram per week, were re-
ported by Forero-Torres et al.15 Brentuximab vedotin (SGN-35), administered 
at a dose ranging from 1.2 to 2.7 mg per kilogram every 3 weeks, is a conju-
gate of cAC10 and antitubulin agent monomethyl auristatin E (MMAE).
The New England Journal of Medicine 
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on August 16, 2014. For personal use only. No other uses without permission. 
 Copyright © 2010 Massachusetts Medical Society. All rights reserved. 
Brentuximab Vedotin and CD30-Positive Lymphomas
n engl j med 363;19 nejm.org november 4, 2010 1821
gate brentuximab vedotin induced durable re-
sponses, with moderate adverse effects, in this 
phase 1 study. Tumor regression was noted in 86% 
of patients, and tumor-related symptoms were re-
lieved in 81% of those in whom such symptoms 
were present. Further testing is warranted on the 
basis of these results.
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